Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD

This study tests a drug that blocks a protein called TSLP, which may trigger inflammation in the airways of people with COPD (chronic obstructive pulmonary disease — a lung condition that causes breathing difficulty). Researchers want to see if this drug reduces flare-ups and airway inflammation. **You may be eligible if...** - You are 40 years or older and have been diagnosed with COPD - You have smoked at least 10 pack-years (e.g., 1 pack a day for 10 years, whether current or ex-smoker) - Your breathing test results fall within a specific range showing moderate-to-severe airflow obstruction - You are already on maintenance inhalers (combinations of LAMA, LABA, and/or ICS) - You have had at least one COPD flare-up in the past year requiring steroids or antibiotics **You may NOT be eligible if...** - You have asthma or another lung disease as your primary diagnosis - You have had a major COPD flare-up in the past 6 weeks - You have significant heart, liver, or immune system problems - You are currently smoking and unwilling to try to quit - You are taking certain medications that could interact with the study drug Talk to your doctor to see if this trial is right for you.